This invention provides a method for determining abnormal metabolization of bone by using genes expressed strongly in osteoclasts, a method for screening compounds having treating and/or prophylactic effects for abnormal metabolization of bone, and a pharmaceutical composition for treatment and/or prophylaxis of abnormal metabolization of bone.This invention provides a method for determining abnormal metabolization of bone by using the expression of human Siglec-15 gene as indicator, a pharmaceutical composition comprising antibodies specifically identifying human Siglec-15 and inhibiting the formation of osteoclasts, and the like.本發明提供使用於破骨細胞中表現強烈的基因檢測骨代謝異常之方法、具有骨代謝異常治療及/或預防效果之化合物之篩選法、及骨代謝異常治療及/或預防用醫藥組成物。提供以人類Siglec-15基因之表現作為指標之骨代謝異常之檢測方法、及含有專一性辨識人類Siglec-15且具有抑制破骨細胞形成活性的抗體的醫藥組成物等。
